Advances in Cancer Research
GPCR Signaling in Cancer
GPCR Signaling in Cancer, Volume 145
Serial Volume Editor: Arun Shukla
Published Date: 21st February 2020
View all volumes in this series: Advances in Cancer Research
1. HERs Transregulation in Cancer Progression: From Discovery to 2020 and Beyond
2. RTKs in Cancer Biology
3. Advances in EGFR Biochemistry and Biology
Yosef Yarden
4. Mouse Models of RTKs/HERs: Lessons and Implications to Biology and Therapy
William Joseph Muller
5. MET Receptor in Oncology: From Biomarker to Therapeutic Target
Ravi Salgia
6. RTKs in Pathobiology of Head & Neck Cancer
Radhakrishna Pillai
7. HER2 or Nuclear HER/RTK in Cancer
Mien-Chie Hung
8. FLT3 in Hematopietic Malignancies: From Pathobiology to Therapeutics
Premkumar Reddy
9. Advances in IGF1R Biology and –directed Cancer Therapeutics
Douglas Yee
10. Advances in Bcr-Abl in Cancer Therapy and Biology
Nandini Verma
11. EphRs in Cancer Development and Progression
Renata Pasqualini
12. RTK-directed Clinical Advances: Trials and Treatments
Masakazu Toi
GPCR Signaling in Cancer, Volume 145, the latest release in the Advances in Cancer Research series, highlights recent developments in the area of GPCRs and cancer biology. Chapters included in this volume cover several GPCRs and their downstream effectors as case examples to highlight their fundamental understanding and therapeutic potential. Specific chapters address the Role of GRKs and beta-arrestins in cancer, Atypical GPCRs in cancer, the Role of a chemokine receptor (CCR) 5 in cancer, Targeting G protein-coupled receptors for therapeutics in cancer, Emerging GPCR signaling pathways in cancer, and more.
G protein-coupled receptors (GPCRs) constitute a large family of cell surface receptors which are involved in nearly every cellular and physiological event. These receptors can recognize a broad array of ligands and they are targeted by nearly one third of the currently prescribed drugs including anti-cancer therapeutics.
Covers the latest concepts in GPCR signaling and their relevancy to cancer biology
Presents new indications for anti-cancer therapeutic programs
Includes sections on cross-talk and signaling networks of GPCRs and effectors in molecular oncology and therapeutics
Primary researchers and clinicians involved in molecular oncology research and cancer therapeutics
About the Serial Volume Editor
Arun Shukla
Dr. Arun K. Shukla obtained his M.Sc. (Master in Science) from the Center for Biotechnology at the Jawaharlal Nehru University in New Delhi, India. Dr. Shukla did his Ph.D. from the Department of Molecular Membrane Biology at the Max Planck Institute of Biophysics in Frankfurt, Germany. His Ph.D. research work was focused on structural studies of G Protein-Coupled Receptors (GPCRs).
Dr. Shukla subsequently carried out his post-doctoral work in the Department of Medicine at the Duke University in North Carolina, USA. During his post-doctoral research work, Dr. Shukla focused on understanding the biophysical and structural basis of ß-arrestin mediated regulation of GPCRs and non-canonical GPCR signaling. Dr. Shukla has served as an Assistant Professor in the Department of Medicine at the Duke University in Durham, North Carolina, USA.
Dr. Shukla is currently an Assistant Professor in Department of Biological Sciences and Bioengineering at the Indian Institute of Technology, Kanpur, India. Dr. Shukla is also an Intermediate Fellow of the Wellcome Trust-DBT India Alliance. The research program in Dr. Shukla's laboratory is focused on understanding the molecular mechanism of activation, signaling and regulation of G Protein-Coupled Receptors.
Indian Institute of Technology, Kanpur, India